Neurogene GAAP EPS of -$1.05
Source: SeekingAlpha
2025-08-11 16:50:23 ET
More on Neurogene
- Neurogene downgraded to Neutral at Baird on regulatory uncertainty
- Seeking Alpha’s Quant Rating on Neurogene
- Historical earnings data for Neurogene
- Financial information for Neurogene
Read the full article on Seeking Alpha
For further details see:
Neurogene GAAP EPS of -$1.05
Neurogene Inc.
NASDAQ: NGNE
NGNE Trading
-4.24% G/L:
$25.175 Last:
6,737 Volume:
$26 Open:
NGNE Latest News
April 28, 2026 07:30:00 am
Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy
April 20, 2026 07:30:00 am
Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors
April 04, 2026 06:40:44 am
Neurogene Inc. (NASDAQ:NGNE) Given Consensus Recommendation of "Moderate Buy" by Brokerages
March 24, 2026 07:30:00 am
Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates
NGNE Stock Data
$263,326,600
13,686,787
0.57%
9
N/A
Pharmaceuticals
Healthcare
US
New York
